Structure-based discovery of a chemical probe targeting the Tudor domain of FMRP
Ontology highlight
ABSTRACT: Fragile X mental retardation protein (FMRP) is an RNA-binding protein whose loss of function is associated with neurodevelopmental disorders, including fragile X syndrome and autism, and whose aberrant overexpression has been linked to immune-related cancers. Here, we report XY6-1, a potent and selective antagonist that targets the tandem Tudor domain (TTD) of FMRP, a methylated-histone reader. Structural and mutagenesis analyses reveal that subtle differences in the shape of the aromatic cage contribute to the selective binding of XY6-1 to FMRP. Multiple orthogonal target engagement assays further demonstrate that XY6-1 specifically binds FMRP in cells and disrupts the interaction between FMRP-TTD and histone H3K79me3, thereby attenuating the DNA damage response (DDR), as evidenced by reduced γH2A.X levels. Collectively, this first-in-class chemical probe XY6-1, along with its fluorescent (XY6-1–FITC) and biotinylated (XY6-1–Biotin) derivatives and the negative control compound XY6-2, constitutes a valuable toolkit for elucidating the underexplored biological functions of FMRP.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Kidney
SUBMITTER:
boyi Li
LAB HEAD: Yunyuan Huang
PROVIDER: PXD072708 | Pride | 2026-07-30
REPOSITORIES: Pride
ACCESS DATA